Abstract
Background: Desidustat (ZYAN1) is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) that stimulates erythropoiesis. Stabilizing HIF via PHI is developing as a new therapeutic approach to treat anemia secondary to chronic kidney disease (CKD). This trial evaluated the safety, tolerability, and efficacy of Desidustat in adult CKD patients with anemia, who were not on dialysis. Methods: This was a Phase 2, randomized, double-blind, 6-week, placebo-controlled, dose-ranging, safety and efficacy study. A total of 117 eligible patients were randomized to 4 arms: 100, 150, 200 mg, or placebo. The investigational product was administered every alternate day for 6 weeks in fasting conditions. The primary endpoint was change in hemoglobin (Hb) from baseline to week 6. Results: Baseline demographics were well balanced among all the treatment arms. In the modified intent-to-treat (mITT) population, a mean Hb increase of 1.57, 2.22, and 2.92 g/dL in Desidustat 100, 150, and 200 mg arms, respectively, was observed post 6 weeks treatment. The responder rate (≥1 g/dL increase) was 66% in 100 mg, 75% in 150 mg, and 83% in 200 mg treatment arms, in the mITT population. Eighteen patients had at least one treatment emergent adverse event (TEAE), and 5 patients reported at least one drug-related mild TEAE. No death or serious adverse event was reported during the trial. Conclusion: There was dose-related increase in Hb across all doses compared to placebo in mITT and per-protocol populations. Desidustat also increased pharmacokinetic parameters Cmax and AUC in dose-related manner. There was no significant change in vital signs, electrocardiographic parameters, or safety laboratory values. Clinical Trial Registration Number CTRI/2017/05/008534 (registered on May 11, 2017).
References
1.
Collins AJ, Ma JZ, Xia A, Ebben J. Trends in anemia treatment with erythropoietin usage and patient outcomes.
Am J Kidney Dis
. 1998 Dec;32(6 Suppl 4):S133–41.2.
Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney disease in the United States.
JAMA
. 2007 Nov;298(17):2038–47.3.
Fishbane S, Nissenson AR. Anemia management in chronic kidney disease.
Kidney Int Suppl
. 2010 Aug;78(117):S3–9.4.
Pergola PE, Spinowitz BS, Hartman CS, Maroni BJ, Haase VH. Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease.
Kidney Int
. 2016 Nov;90(5):1115–22.5.
Kidney Disease Improving Global Outcomes (KDIGO) CKD Work Group: KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl (2011). 2012;2(4):279.
6.
Locatelli F, Aljama P, Canaud B, Covic A, De Francisco A, Macdougall IC, et al.; Anaemia Working Group of European Renal Best Practice (ERBP). Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study.
Nephrol Dial Transplant
. 2010 Sep;25(9):2846–50.7.
Tsubakihara Y, Nishi S, Akiba T, Hirakata H, Iseki K, Kubota M, et al. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Ther Apher Dial
. 2010 Jun;14(3):240–75.8.
Muirhead N. A rationale for an individualized haemoglobin target.
Nephrol Dial Transplant
. 2002;17(90006 Suppl 6):2–7.9.
Regidor DL, Kopple JD, Kovesdy CP, Kilpatrick RD, McAllister CJ, Aronovitz J, et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients.
J Am Soc Nephrol
. 2006 Apr;17(4):1181–91.10.
Collins AJ. Anaemia management prior to dialysis: cardiovascular and cost-benefit observations.
Nephrol Dial Transplant
. 2003 Jun;18 Suppl 2:ii2–6.11.
Benz R, Schmidt R, Kelly K, Wolfson M. Epoetin alfa once every 2 weeks is effective for initiation of treatment of anemia of chronic kidney disease.
Clin J Am Soc Nephrol
. 2007 Mar;2(2):215–21.12.
Valliant A, Hofmann RM. Managing dialysis patients who develop anemia caused by chronic kidney disease: focus on peginesatide.
Int J Nanomedicine
. 2013;8:3297–307.13.
Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al.; CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia.
N Engl J Med
. 2006 Nov;355(20):2071–84.14.
Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, et al.; TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.
N Engl J Med
. 2009 Nov;361(21):2019–32.15.
Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al.; CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease.
N Engl J Med
. 2006 Nov;355(20):2085–98.16.
Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, et al. Secondary analysis of the CHOIR trial epoetin-α dose and achieved hemoglobin outcomes.
Kidney Int
. 2008 Sep;74(6):791–8.17.
Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA, et al.; Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) Investigators. Erythropoietic response and outcomes in kidney disease and type 2 diabetes.
N Engl J Med
. 2010 Sep;363(12):1146–55.18.
Martin ER, Smith MT, Maroni BJ, Zuraw QC, deGoma EM. Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease.
Am J Nephrol
. 2017;45(5):380–8.19.
Joharapurkar AA, Pandya VB, Patel VJ, Desai RC, Jain MR. Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases.
J Med Chem
. 2018 Aug;61(16):6964–82.20.
Paliege A, Rosenberger C, Bondke A, Sciesielski L, Shina A, Heyman SN, et al. Hypoxia-inducible factor-2α-expressing interstitial fibroblasts are the only renal cells that express erythropoietin under hypoxia-inducible factor stabilization.
Kidney Int
. 2010 Feb;77(4):312–8.21.
Kapitsinou PP, Liu Q, Unger TL, Rha J, Davidoff O, Keith B, et al. Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia.
Blood
. 2010 Oct;116(16):3039–48.22.
Maxwell PH, Eckardt KU. HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond.
Nat Rev Nephrol
. 2016 Mar;12(3):157–68.23.
Marks E, Goggins BJ, Cardona J, Cole S, Minahan K, Mateer S, et al. Oral delivery of prolyl hydroxylase inhibitor: AKB-4924 promotes localized mucosal healing in a mouse model of colitis.
Inflamm Bowel Dis
. 2015 Feb;21(2):267–75.24.
Kansagra KA, Parmar D, Jani RH, Srinivas NR, Lickliter J, Patel HV, et al. Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volunteers.
Clin Pharmacokinet
. 2018 Jan;57(1):87–102.25.
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al.; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate.
Ann Intern Med
. 2009 May;150(9):604–12.26.
Besarab A, Provenzano R, Hertel J, Zabaneh R, Klaus SJ, Lee T, et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients.
Nephrol Dial Transplant
. 2015 Oct;30(10):1665–73.27.
Chen N, Qian J, Chen J, Yu X, Mei C, Hao C, et al. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China.
Nephrol Dial Transplant
. 2017 Aug;32(8):1373–86.28.
Holdstock L, Meadowcroft AM, Maier R, Johnson BM, Jones D, Rastogi A, et al. Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia.
J Am Soc Nephrol
. 2016 Apr;27(4):1234–44.29.
Macdougall IC, Akizawa T, Berns JS, Bernhardt T, Krueger T. Effects of Molidustat in the Treatment of Anemia in CKD.
Clin J Am Soc Nephrol
. 2019 Jan;14(1):28–39.30.
Sugahara M, Tanaka T, Nangaku M. Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease.
Kidney Int
. 2017 Aug;92(2):306–12.31.
Eleftheriadis T, Liakopoulos V, Antoniadi G, Kartsios C, Stefanidis I. The role of hepcidin in iron homeostasis and anemia in hemodialysis patients.
Semin Dial
. 2009 Jan-Feb;22(1):70–7.32.
Provenzano R, Besarab A, Sun CH, Diamond SA, Durham JH, Cangiano JL, et al. Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD.
Clin J Am Soc Nephrol
. 2016 Jun;11(6):982–91.33.
Koury MJ, Haase VH. Anaemia in kidney disease: harnessing hypoxia responses for therapy.
Nat Rev Nephrol
. 2015 Jul;11(7):394–410.34.
Yousaf F, Spinowitz B. Hypoxia-Inducible Factor Stabilizers: a New Avenue for Reducing BP While Helping Hemoglobin?
Curr Hypertens Rep
. 2016 Mar;18(3):23.35.
Weinhandl ED, Gilbertson DT, Collins AJ. Association of mean weekly epoetin alfa dose with mortality risk in a retrospective cohort study of Medicare hemodialysis patients.
Am J Nephrol
. 2011;34(4):298–308.36.
Kalantar-Zadeh K, Lee GH, Miller JE, Streja E, Jing J, Robertson JA, et al. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients.
Am J Kidney Dis
. 2009 May;53(5):823–34.37.
McCullough PA, Barnhart HX, Inrig JK, Reddan D, Sapp S, Patel UD, et al. Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease.
Am J Nephrol
. 2013;37(6):549–58.38.
Inrig JK, Sapp S, Barnhart H, Patel UD, Reddan D, Singh A, et al. Impact of higher hemoglobin targets on blood pressure and clinical outcomes: a secondary analysis of CHOIR.
Nephrol Dial Transplant
. 2012 Sep;27(9):3606–14.39.
Okazaki M, Komatsu M, Kawaguchi H, Tsuchiya K, Nitta K. Erythropoietin resistance index and the all-cause mortality of chronic hemodialysis patients.
Blood Purif
. 2014;37(2):106–12.40.
Kilpatrick RD, Critchlow CW, Fishbane S, Besarab A, Stehman-Breen C, Krishnan M, et al. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients.
Clin J Am Soc Nephrol
. 2008 Jul;3(4):1077–83.41.
Unger EF, Thompson AM, Blank MJ, Temple R. Erythropoiesis-stimulating agents–time for a reevaluation.
N Engl J Med
. 2010 Jan;362(3):189–92.42.
Shibata T, Nomura Y, Takada A, Ueno M, Katashima M, Yazawa R, et al. Evaluation of Food and Spherical Carbon Adsorbent Effects on the Pharmacokinetics of Roxadustat in Healthy Nonelderly Adult Male Japanese Subjects.
Clin Pharmacol Drug Dev
. 2019 Apr;8(3):304–13.43.
Johnson BM, Stier BA, Caltabiano S. Effect of food and gemfibrozil on the pharmacokinetics of the novel prolyl hydroxylase inhibitor GSK1278863.
Clin Pharmacol Drug Dev
. 2014 Mar;3(2):109–17.44.
Caltabiano S, Mahar K, Lister K, Tenero D, Ravindranath R, Cizman B, Cobitz A: The drug interaction potential of daprodustat when coadministered with pioglitazone, rosuvastatin, or trimethoprim in healthy subjects.
Pharmacol Res Perspect
. 2018;6(2):e00327.45.
Johnson BM, Stier BA, Caltabiano S. Effect of food and gemfibrozil on the pharmacokinetics of the novel prolyl hydroxylase inhibitor GSK1278863.
Clin Pharmacol Drug Dev
. 2014 Mar;3(2):109–17.46.
Goel HL, Mercurio AM. VEGF targets the tumour cell.
Nat Rev Cancer
. 2013 Dec;13(12):871–82.
